Appendix 3Y – Change of Director's Interest Notices

26 June 2026

Pursuant to ASX Listing Rule 3.19A.2, directors Lil Bianchi and John Livingston provide the attached Appendix 3Y disclosures.

These forms disclose the change in each director's interest in 4DMedical Limited as follows:

- **Lil Bianchi:** Exercised 308,394 options, increasing her shareholding by 308,394 shares.
- **John Livingston:** Exercised 247,648 options, increasing his shareholding by 247,648 shares.

For avoidance of doubt, no Directors have sold any shares.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate	Administration	Media Enquiries
Investor Relations	Company Secretary	Julia Maguire
investor.relations@4dmedical.com	companysecretary@4dmedical.com	julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio** and 2026 acquisition of **contextflow**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**4DMedical Limited**
ABN	**31 161 684 831**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ms Lilian Bianchi
Date of last notice	18 December 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Lemon Peel Pty Ltd as trustee for Lemon Peel Superannuation Fund: • director of Lemon Peel Pty Ltd; • beneficiary of Lemon Peel Superannuation Fund
Date of change	19 June 2026
No. of securities held prior to change	290,212 ordinary shares 308,394 unquoted options with a nil exercise price and expiry date of 30 June 2030.
Class	Ordinary shares Unquoted options with a nil exercise price and expiry date of 30 June 2030
Number acquired	308,394 ordinary shares

Number disposed	308,394 unquoted options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	598,606 ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of unlisted options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

227Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**4DMedical Limited**
ABN	**31 161 684 831**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Livingston
Date of last notice	22 January 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary shares in which the beneficial interest is held by John Livingston Pty Ltd, an entity controlled by John Livingston (registered holder: Colonial First State Inv Ltd <4916557 JOHN A/C>); and Ordinary shares in which the beneficial interest is held by JKEL Super Pty Ltd, an entity in which John Livingston has a voting power above 20% and thus is deemed by Section 608(3) of the Corporations Act 2001 to have the same relevant interest (registered holder: Colonial First State Inv Ltd <4916510 JKEL A/C>).
Date of change	19 June 2026

No. of securities held prior to change	**Direct** 60,147 fully paid ordinary shares **Indirect** *Colonial First State Inv Ltd <4916557 JOHN A/C>) (beneficial holder John Livingston Pty Ltd)* 424,008 fully paid ordinary shares 247,648 unquoted options with a nil exercise price and expiry date of 30 June 2030. *Colonial First State Inv Ltd <4916510 JKEL A/C (beneficial holder: JKEL Super Pty Ltd* 1,501,344 ordinary fully paid shares
Class	Ordinary Shares Unquoted Options with a nil exercise price and expiry date of 30 June 2030
Number acquired	247,648 Ordinary Shares
Number disposed	247,648 Unquoted Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	**Direct** 60,147 fully paid ordinary shares **Indirect** *Colonial First State Inv Ltd <4916557 JOHN A/C>) (beneficial holder John Livingston Pty Ltd)* 671,656 fully paid ordinary shares *Colonial First State Inv Ltd <4916510 JKEL A/C (beneficial holder: JKEL Super Pty Ltd* 1,501,344 ordinary fully paid shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of unquoted options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.